This is particularly likely in the case of breast cancer cells where ErbB2 is amplified and over-expressed, leading to the formation of ErbB2-containing heterodimers in a ligand-independent manner (Worthylake et al., 1999; Yarden and Sliwkowski, 2001). Here, ERBB2 is linked to breast carcinoma.